ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.00%
Dow Jones
40,211.72
0.00%
US Dollar vs MXN
17.74515
0.08%
Brent Oil
83.005
-1.58%
Bitcoin
63,869.16
-1.51%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Noticias

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CTMX
FechaHoraFuenteTítuloSímboloCompañía
11/07/202205:18TipRanksAnalyst Explains Why They Downgraded Their Rating on CytomX Therapeutics (CTMX)NASDAQ:CTMXCytomX Therapeutics Inc
08/07/202216:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CTMXCytomX Therapeutics Inc
07/07/202203:15TipRanksWhy Did Mizuho Securities Downgrade CytomX Therapeutics’ Stock?NASDAQ:CTMXCytomX Therapeutics Inc
06/07/202215:05GlobeNewswire Inc.CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast CancerNASDAQ:CTMXCytomX Therapeutics Inc
21/06/202215:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CTMXCytomX Therapeutics Inc
17/06/202215:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CTMXCytomX Therapeutics Inc
16/06/202207:00GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
01/06/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
26/05/202207:00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
05/05/202215:15GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
28/04/202207:00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022NASDAQ:CTMXCytomX Therapeutics Inc
27/04/202215:25Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CTMXCytomX Therapeutics Inc
27/04/202215:23Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CTMXCytomX Therapeutics Inc
14/04/202215:15GlobeNewswire Inc.CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
28/03/202215:13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CTMXCytomX Therapeutics Inc
23/03/202215:15GlobeNewswire Inc.CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
17/03/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022NASDAQ:CTMXCytomX Therapeutics Inc
04/03/202216:23Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CTMXCytomX Therapeutics Inc
04/03/202216:14Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CTMXCytomX Therapeutics Inc
02/03/202210:43TipRanksJ.P. Morgan Thinks CytomX Therapeutics’ Stock is Going to RecoverNASDAQ:CTMXCytomX Therapeutics Inc
01/03/202222:10TipRanksMizuho Securities Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)NASDAQ:CTMXCytomX Therapeutics Inc
01/03/202215:15GlobeNewswire Inc.CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
28/02/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
22/02/202207:00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022NASDAQ:CTMXCytomX Therapeutics Inc
14/02/202216:08Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CTMXCytomX Therapeutics Inc
07/02/202208:00GlobeNewswire Inc.CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating OfficerNASDAQ:CTMXCytomX Therapeutics Inc
19/01/202207:00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
05/01/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
29/12/202110:19Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:CTMXCytomX Therapeutics Inc
27/12/202105:56TipRanksIs CytomX Stock a Buy Following Disappointing Cancer Therapy Results? Analyst Weighs InNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Su Consulta Reciente

NASDAQ
CNXA
Connexa Sports Technolog...
TSX
CUF.UN
Cominar Real Estate Inve...
NYSE
HYF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados